FIELD: medicine; pharmaceutics.
SUBSTANCE: invention relates to the field of medicine and pharmaceutics and represents a method for prediction of the clinical effectiveness evaluation of dapoxetine for treating disorders accompanied by development of depressive symptoms, by results of genotyping using polymorphic markers of CYP2D6 genes, It differs from known methods in that it involves calculating the resultant change in the rate of biotransformation of dapoxetine, the results of which are used to recommend increasing or decreasing the dose of dapoxetine or replacing the drug.
EFFECT: technical result consists in optimizing the dosage regimen of dapoxetine in implementing the method according to the invention, which is based on analysis of results of genotyping by polymorphic markers, capable of influencing the change in activity of genes coding isoenzymes of biotransformation of dapoxetine.
1 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF ESTIMATING THE EFFECTIVENESS OF MIRTAZAPINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPMENT OF DEPRESSIVE SYMPTOMS | 2019 |
|
RU2734347C1 |
| METHOD OF ESTIMATING THE EFFICACY OF FLUVOXAMINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPMENT OF DEPRESSIVE SYMPTOMS | 2019 |
|
RU2722834C1 |
| METHOD FOR PREDICTING THE EFFICACY OF LEVOMEPROMAZINE THERAPY FOR TREATING DISORDERS ACCOMPANIED BY DEVELOPING PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695657C1 |
| METHOD OF ESTIMATING THE EFFICACY OF THE PROMAZINE THERAPY FOR TREATING DISORDERS ACCOMPANYING DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695659C1 |
| METHOD FOR PREDICTION OF CHLORPROMAZINE THERAPY EFFECTIVENESS EVALUATION FOR TREATING DISORDERS ACCOMPANYING DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695658C1 |
| METHOD OF ESTIMATING THE EFFICACY OF FLUPHENAZINE THERAPY FOR TREATING DISORDERS ACCOMPANYING DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695821C1 |
| METHOD OF ESTIMATING THE CLINICAL EFFECTIVENESS OF TRIFLUOPERAZINE FOR TREATING DISORDERS ACCOMPANYING DEVELOPING PSYCHOTIC SYMPTOMS | 2018 |
|
RU2695820C1 |
| METHOD FOR PREDICTING THE EFFICIENCY OF HALOPERIDOL THERAPY FOR THE TREATMENT OF DISORDERS ACCOMPANIED BY THE DEVELOPMENT OF PSYCHOTIC SYMPTOMS | 2017 |
|
RU2643944C1 |
| METHOD FOR CHOOSING THE STARTING SCHEME OF POSTOPERATIVE ANESTHESIA IN PATIENTS AFTER VIDEOLAPAROSCOPIC CHOLECYSTECTOMY | 2021 |
|
RU2779003C1 |
| METHOD FOR IMPROVING DRUG USE SAFETY IN TREATING PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME | 2018 |
|
RU2690522C1 |
